Scarica l'app Stockscreener
0.00
0.00%
0.00
Precedente Chiudi:
$0.00
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
Capitalizzazione di mercato:
$N/A
Reddito:
$1.65M
Utile/perdita netta:
$-5.91M
Rapporto P/E:
0.00
EPS:
-0.1707
Flusso di cassa netto:
$-3.03M
1 W Prestazione:
+0.00%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$0.00
Vitro Biopharma, Inc. Stock (VTRO) Company Profile
Nome
Vitro Biopharma, Inc.
Settore
Industria
Telefono
(720) 859-4120
Indirizzo
4621 TECHNOLOGY DRIVE, GOLDEN
Confronta VTRO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRO
Vitro Biopharma, Inc.
|
0.00 | 0 | 1.65M | -5.91M | -3.03M | -0.1707 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Vitro Biopharma, Inc. Borsa (VTRO) Ultime notizie
Vitro Biopharma Receives ISO 13485 Certification Supporting its Stem Cell Medical Tourism Initiative - ACCESS Newswire
Vitro Biopharma Retains Leading Health Care Executive as Acting Director of Regulatory Affairs & Director - ACCESS Newswire
10 cultured meat companies driving sustainable food in 2025 - Labiotech.eu
Vitro Biopharma's AlloRx Stem Cell TherapyFeatured in New York Times Article on Health Secretary Kennedy's, Vision for Expanding Access to Regenerative Medicine - ACCESS Newswire
Vitro Biopharma's AlloRx Stem Cell Therapy Featured in New York Times Article on Health Secretary Kennedy's Vision for Expanding Access to Regenerative Medicine - ACCESS Newswire
GC Genome plans $30M IPO to diversify genomic products, suppliers - BioWorld MedTech
Vitro Biopharma, Inc. announced a financing transaction - marketscreener.com
Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells(R) to Treat COVID-19 - ACCESS Newswire
Vitro Biopharma’s CEO Elaborates on Merger-Driven Growth Acceleration in an Interview with the Wall Street Analyst - ACCESS Newswire
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - CRISPR Medicine News
Press Release Distribution & PR Platform - ACCESS Newswire
Contrasting Vitro Diagnostics (OTCMKTS:VODG) and Vaxcyte (NASDAQ:PCVX) - Defense World
Emulate Applauds FDA’s Roadmap to Reduce Animal Testing and Embrace Organ-Chip Technologies - BioSpace
Vitro Diagnostics (OTCMKTS:VODG) & Fennec Pharmaceuticals (NASDAQ:FENC) Head to Head Survey - Defense World
Vitro Biopharma Announces Early 2016 Results: Increased Revenue and Expansion Activities to Fuel Growth - ACCESS Newswire
Dealmaking Quarterly Statistics, Q2 2022 - insights.citeline.com
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product - Yahoo Finance
Vitro Biopharma Products Advance Pancreatic Cancer Research - ACCESS Newswire
Vitro Biopharma Revenues Increase in Early 2014: Plans Trials of Endogenous Stem Cell Activation for Therapeutic Benefit - ACCESS Newswire
Best Biotech Stocks to Buy in 2025 - The Motley Fool
Vitro Biopharma Announces Advances in Stem Cell Therapy without Transplants - ACCESS Newswire
What Stem Cell Clinics Do You Trust? - BioInformant
How a virtual company leveraged data to accelerate drug development for neurodegenerative diseases - Labiotech.eu
Dealmaking Quarterly Statistics, Q4 2024 - insights.citeline.com
Vitro Diagnostics (OTCMKTS:VODG) vs. HilleVax (NASDAQ:HLVX) Financial Review - Defense World
Reviewing Cyclo Therapeutics (NASDAQ:CYTH) and Vitro Diagnostics (OTCMKTS:VODG) - Defense World
Financing Quarterly Statistics, Q4 2024 - Citeline
Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner - Business Wire
Vitro Biopharma Inc. January 31st 2021, 1st Quarter ended Financial Results of Operations and Shareholder Letter - ACCESS Newswire
Achieving success in biopharma with recombinant antibody technology - News-Medical
Onconetix Resolves Nasdaq Compliance Issue After Late Q3 Filing - Stock Titan
The In Vitro Activity of Rezafungin Against Uncommon Species of CandidaWinkler2024Mycoses - Wiley Online Library
In Vitro Diagnostics (IVD) Market Size to Surpass USD 157.56 Billion by 2034 - BioSpace
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vitro-In Vivo Extrapolation Methods for Complex Formulations - Business Wire
Vitro Biopharma, Inc. announced that it has received $1 million in funding - MarketScreener
Top 5 In-Vitro Diagnostics [IVD] Companies, Worldwide by 2024 - Fortune Business Insights
Fapon Biotech Delivers Antigen Diagnostic Solutions to Help Control Monkeypox Outbreak in Africa - PR Newswire
Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity - ACS Publications
(PDF) Comprehensive Review on Drug Discovery and Development Process - researchgate.net
A biotech working on a new approach to IVF raises $33M in fresh funding - BioPharma Dive
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024 - Yahoo Finance
GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications - BioSpace
FDA defends lab test rule, as critics fear industry upheaval - BioPharma Dive
21 Atlanta Biotech Companies Making Waves in the Life Sciences Sector - Built In
ProteoMixture: A cell type deconvolution tool for bulk tissue proteomic data - ScienceDirect.com
Women’s health company Obseva to wind down, lay off staff - BioPharma Dive
Vitro Biopharma, Inc. Announces Chief Financial Officer Changes - MarketScreener
The TIM Company Appoints Biotech Veteran Dr. Behzad Mahdavi as Transformative CEO and Board Member - PR Newswire
Swiss investment firm denies acquisition bid for Boryung Biopharma - koreabiomed.com
Asep Medical Holdings Inc. Signs Joint Venture Agreement with Leading Chinese Medical Diagnostics Company Sansure Biotech Inc. - PR Newswire
Vitro Biopharma, Inc. Azioni (VTRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.24%
3.39%
Capitalizzazione:
|
Volume (24 ore):